We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies.
DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tests are designed for hospital and private testing laboratories in the markets of immunodiagnostics and molecular diagnostics.
The Simplexa COVID-19 Direct kit allows for fast results directly from BAL, nasal swab, nasal wash/aspirate, nasopharyngeal swab and saliva specimens, eliminating traditional RNA extraction steps. The assay has demonstrated excellent clinical agreement and turnaround time, allowing for optimal allocation of critical resources and effective patient management decision making.
DiaSorin S.p.A. has entered into an agreement to acquire Siemens Healthineers’ micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.
DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tests are designed for hospital and private testing laboratories in the markets of immunodiagnostics and molecular diagnostics.
The Simplexa Flu A/B & RSV Kit is intended for the reliable detection and differentiation of influenza A virus, influenza B virus and RSV. Intended for use on the LIASON MDX, the kit is capable of running 94 patient samples at the same time.
